Understand the source comparison
Cerebrolysin vs Other Research Peptides: Mechanism Comparison
Cerebrolysin Multi-target neurotrophic factor mimetic (BDNF, NGF, GDNF analogues) Central nervous system (neurons, synapses) Yes. Peptides <10 kDa cross efficiently Direct exogenous delivery 13+ RCTs in stroke, dementia, TBI with meta-analysis confirmation Gol
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- Multi-target neurotrophic factor mimetic (BDNF, NGF, GDNF analogues)
- Central nervous system (neurons, synapses)
- Yes. Peptides <10 kDa cross efficiently
- Direct exogenous delivery
- 13+ RCTs in stroke, dementia, TBI with meta-analysis confirmation
- Gold standard for acute neurological injury research
- Semax
- Melanocortin-4 receptor agonist (increases endogenous BDNF expression)
- Central nervous system (hippocampus, cortex)
- Yes. Heptapeptide structure
- Indirect (upregulates endogenous production)
- Limited. Primarily Russian clinical studies
- Strong cognitive enhancement tool, weaker acute injury evidence
- BPC-157
- VEGF receptor activation, nitric oxide signaling, angiogenesis
- Peripheral tissue (tendon, muscle, GI mucosa)
- No. Limited CNS penetration
- None
- None (preclinical only)
- Best-in-class for tissue repair studies, irrelevant for neuroprotection
- TB-500
- Actin upregulation, cell migration, ECM remodeling
- Peripheral tissue (muscle, cardiac, vascular)
- No. 43 amino acids too large
- Phase II cardiac repair trials ongoing
- Proven regenerative peptide for musculoskeletal research
- Selank
- GABAergic and enkephalinergic modulation (anxiolytic, stress adaptation)
- Central nervous system (amygdala, limbic)
- Yes. Tuftsin-derived hexapeptide
- Limited. Russian neuropsychiatric studies
- Excellent stress resilience research tool, not for acute injury